Kanagawa Cardiovascular and Respiratory Center
Kanagawa Yokohama, Japan
Medical center in Yokohama
6 Chome-16-1 Tomiokahigashi, Kanazawa Ward, Yokohama, Kanagawa 236-0051
About Kanagawa Cardiovascular and Respiratory Center
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Boehringer Ingelheim
15
Pfizer
4
Hoffmann-La Roche
3
Actelion
2
Chugai Pharmaceutical
2
Galapagos NV
2
Savara Inc.
2
Associations for Establishment of Evidence in Interventions
1
AstraZeneca
1
Bayer
1
Eli Lilly and Company
1
Clinical Trials at Kanagawa Cardiovascular and Respiratory Center
During the past decade, Kanagawa Cardiovascular and Respiratory Center conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 19 clinical trials were completed, i.e. on
average, 65.5% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 12 clinical trials were completed. i.e. 109.1%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
2008-04-01
2010-05-01
Completed
128
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
2009-08-14
2017-03-16
Completed
345
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
2011-01-13
2016-11-30
Completed
343
The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)
2010-10-01
2011-04-01
Completed
47
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
2010-11-11
2018-08-21
Completed
6,103
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
2011-06-16
2015-09-14
Completed
878
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Kanagawa Cardiovascular and Respiratory Center" #1 sponsor was "Boehringer Ingelheim" with 15 trials, followed by "Pfizer" with 4 trials
sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Actelion" with 2 trials sponsored and "Chugai Pharmaceutical"
with 2 trials sponsored. Other sponsors include 8 different institutions and
companies that sponsored additional 16 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Kanagawa Cardiovascular and Respiratory Center"
#1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "NPO International TRI Network" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were
collaborators in the rest 5 trials.
Clinical Trials Conditions at Kanagawa Cardiovascular and Respiratory Center
According to Clinical.Site data, the most researched conditions in "Kanagawa Cardiovascular and Respiratory Center" are
"Idiopathic Pulmonary Fibrosis" (11 trials), "Lung Diseases, Interstitial" (4 trials), "Heart Failure" (3 trials), "Acute Myocardial Infarction" (2 trials) and "Autoimmune Pulmonary Alveolar Proteinosis" (2 trials). Many other conditions were trialed in "Kanagawa Cardiovascular and Respiratory Center" in a lesser frequency.
Clinical Trials Intervention Types at Kanagawa Cardiovascular and Respiratory Center
Most popular intervention types in "Kanagawa Cardiovascular and Respiratory Center" are "Drug" (33 trials), "Device" (3 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (15 trials), "Nintedanib" (6 trials), "BI 1015550" (3 trials), "Carboplatin" (3 trials) and "Empagliflozin" (3 trials). Other intervention names were less common.
Clinical Trials Genders at Kanagawa Cardiovascular and Respiratory Center
The vast majority of trials in "Kanagawa Cardiovascular and Respiratory Center" are
39 trials for "All" genders.
Clinical Trials Status at Kanagawa Cardiovascular and Respiratory Center
Currently, there are NaN active trials in "Kanagawa Cardiovascular and Respiratory Center".
undefined are not yet recruiting,
7 are recruiting,
2 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 26 completed trials in Kanagawa Cardiovascular and Respiratory Center,
undefined suspended trials,
and 4 terminated clinical trials to date.
Out of the total trials that were conducted in Kanagawa Cardiovascular and Respiratory Center, 1 "Phase 1"
clinical trials were conducted, 5 "Phase 2" clinical
trials and 27 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 2 trials that are defined as “Not Applicable".